Page 24 - பல்கலைக்கழகம் ஆஃப் வடக்கு கரோலினா பள்ளி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

N.J. drugmaker Merck reports new antiviral COVID drug quickly reduces virus Updated Mar 06, 2021; Posted Mar 06, 2021 Clinical trials of a new antiviral COVID treatment were said to be promising, Merck announced on Saturday.AP Photo/Matt Rourke, file Facebook Share New Jersey-based Merck said Saturday that the experimental antiviral drug molnupiravir it has been developing with Ridgeback Bio showed a quick reduction of the infectious virus in a study among participants with early COVID-19. “We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings,” said Roy Baynes, head of global clinical development and chief medical officer at Merck Research Laboratories.

District of columbiaUnited statesWhite houseWilliam fischerRidgeback biotherapeuticsRidgeback bioRoy baynesMerck research laboratoriesEmory universityBiomedical advanced researchUs department of healthHuman servicesDevelopment authorityHuman health at merckUniversity of north carolina school medicineNew jersey based merck